On August 7, 2023, ACLARIS THERAPEUTICS ($NASDAQ:ACRS) released their earnings report for the second quarter of the fiscal year 2023, which ended on June 30, 2023. They reported total revenue of USD 1.9 million, a 22.2% increase compared to the same quarter the previous year. However, their net income was USD -29.6 million, down from the -20.5 million reported in the same quarter of the previous year.
On Monday, ACLARIS THERAPEUTICS stock opened at a price of $10.0 and closed at $9.1, which was a 7.2% drop from the previous closing price of $9.8. Despite the impressive increase in revenue and income, the earnings report still caused a sell-off in the stock due to the market’s expectations for higher profits. In total, these costs negatively impacted the company’s profits for the quarter. Overall, ACLARIS THERAPEUTICS reported an impressive quarter but still failed to meet market expectations. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Aclaris Therapeutics. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Aclaris Therapeutics. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Aclaris Therapeutics. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Aclaris Therapeutics are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Aclaris Therapeutics Stock Fair Value
As GoodWhale, we conducted an analysis of ACLARIS THERAPEUTICS‘s wellbeing. Our proprietary Valuation Line computed a fair value of ACLARIS THERAPEUTICS share to be around $38.6. However, the stock is currently traded at $9.1, which is undervalued by 76.4%. This presents an opportunity for investors who are looking for a good value investment. More…
Risk Rating Analysis
Star Chart Analysis
It is one of many companies operating in the field, including Guardant Health Inc, Joinn Laboratories (China) Co Ltd, and Burning Rock Biotech Ltd. All of these companies are working to bring innovative treatments for skin and hair disorders to the market.
– Guardant Health Inc ($NASDAQ:GH)
Guardant Health Inc is a precision oncology company that develops and commercializes non-invasive tests for advanced cancer. The company has a market capitalization of 2.86 billion dollars as of 2022. Guardant Health Inc has a negative Return on Equity of -150.22%, which suggests that its current shareholders are not being rewarded for their investments. This low return is likely due to the company’s high spending on research and development in order to stay competitive in the rapidly evolving field of precision oncology.
– Joinn Laboratories (China) Co Ltd ($SHSE:603127)
Joinn Laboratories (China) Co Ltd is a leading global biotechnology company that develops, manufactures, and markets innovative products for the health and wellness industry. With a market capitalization of 27.83B as of 2022, Joinn Laboratories has been able to deliver strong returns on equity of 9.11%. This company has become a leader in the biotech industry due to its commitment to research and development, and its ability to stay ahead of the competition. Joinn Laboratories is focused on improving the quality of life for its customers through its cutting-edge products and services.
– Burning Rock Biotech Ltd ($NASDAQ:BNR)
Burning Rock Biotech Ltd is a Chinese biotechnology company focused on the development of cancer diagnostics and precision medicine. The company has a market cap of 219.91M as of 2022, indicating that it is a large and well-established company. Its Return on Equity of -46.46% indicates that the company is currently experiencing financial difficulty. This could be due to the high costs associated with developing diagnostic and precision medicine technologies, which may eventually lead to greater returns in the future.
ACLARIS THERAPEUTICS reported their earnings for the second quarter of fiscal year 2023, ending June 30 2023, with total revenue at USD 1.9 million, a 22.2% increase year-on-year. Net income was USD -29.6 million, a decrease from the -20.5 million reported the year before. The stock price moved down the same day in reaction to the results.
As an investing analysis, this quarter’s figures show a healthy revenue growth, although profitability remains an issue. Investors should monitor whether ACLARIS THERAPEUTICS can improve their profitability in the near future.